GlassScriptPhysician profile
Sara Martin
NPI 1720352180
$847.87
in general payments reported to CMS, 2019-2025
17 companies · $283 in 2025
The $283 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $36.71 · 2022: $85.24 · 2023: $267 · 2024: $176 · 2025: $283.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $551 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $550.92 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $242.54 | 2022-2025 | Prolia, Evenity, Otezla |
| Octapharma USA, INC. | $114.63 | 2023 | Fibryga |
| Novartis Pharmaceuticals Corporation | $83.49 | 2023-2024 | |
| Abbvie INC. | $68.86 | 2024-2025 | |
| Pfizer INC. | $61.35 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $44.43 | 2023 | Imbruvica, Epkinly |
| Jazz Pharmaceuticals INC. | $36.71 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.16 | 2022-2023 | |
| Astrazeneca Pharmaceuticals LP | $28.28 | 2022-2023 | Farxiga |
| Optinose US, INC. | $25.02 | 2024 | |
| Sunovion Pharmaceuticals INC. | $21.96 | 2022 | |
| Blueprint Medicines Corporation | $18.61 | 2024 | Ayvakit |
| Lilly USA, LLC | $16.52 | 2022 | |
| Glaxosmithkline, LLC. | $14.40 | 2024 | Shingrix, Arexvy |
| Astellas Pharma US INC | $14.39 | 2023 | Veozah |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $13.57 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $12.95 | 2023 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.